Noman Ashraf
Internal Medicine · Tampa, FLNPI 1437395191
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,398 of the $8,712 with a category attached, or 73.4%. 26 manufacturers reported payments, led by Johnson & Johnson at 34.8% of the total. 2025 is the largest year on record at $3,849, more than ten times the $304 reported in 2022. Among internal medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 61 payments — averaging $142.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$3K
- AstraZeneca$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Gilead$194
- Servier Pharmaceuticals LLC$165
- Boston Scientific$149
- plus $1K from 20 others
Across 4 payments — averaging $839.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$3K
What the payments were for
- Consulting fees$6,39873%
- Travel & lodging$851%
- Food & beverage$2,22926%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 4 | $3,028 |
| AstraZeneca(2 entities) | 8 | $2,014 |
| E.r. Squibb & Sons, L.L.C. | 4 | $1,931 |
| Gilead | 4 | $194 |
| Servier Pharmaceuticals LLC | 2 | $165 |
| Boston Scientific | 1 | $149 |
| Daiichi Sankyo Inc. | 4 | $132 |
| Lilly USA, LLC | 5 | $125 |
| Incyte Corporation | 2 | $123 |
| AbbVie | 1 | $121 |
| Janssen Scientific Affairs, LLC | 1 | $104 |
| Rigel Pharmaceuticals, Inc. | 3 | $79 |
| Boehringer Ingelheim | 3 | $75 |
| Exelixis Inc. | 1 | $74 |
| Novartis | 3 | $64 |
| Eisai Inc. | 3 | $48 |
| Pharmacosmos Therapeutics Inc. | 2 | $47 |
| Tempus AI, Inc | 2 | $47 |
| Amgen | 1 | $32 |
| Mirati Therapeutics, Inc. | 1 | $29 |
| Sanofi | 1 | $26 |
| Springworks Therapeutics, Inc. | 1 | $25 |
| Karyopharm Therapeutics Inc. | 1 | $24 |
| Fennec Pharmaceuticals, Inc. | 1 | $23 |
| Caris MPI, Inc. | 1 | $19 |
| Merck | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RYBREVANT$2,943
- TheraSphere Y90 Glass Microspheres 10 GBq$149
- CALQUENCE$125
- Trodelvy$124
- Venclexta$121
How this compares
$8,712 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 36 | $585,104 |
| KeytrudaPembrolizumab | 30 | $318,288 |
| Oxycodone Hcl | 86 | $1,860 |
| Ondansetron OdtOndansetron | 95 | $1,570 |
| Dexamethasone | 178 | $535 |
| Gabapentin | 31 | $441 |
| Omeprazole | 12 | $316 |
| Mirtazapine | 12 | $315 |
| Prochlorperazine Maleate | 18 | $311 |
| Nystatin | 13 | $271 |
| Ondansetron Hcl | 11 | $233 |
| Pantoprazole Sodium | 27 | $190 |
| Tramadol Hcl | 21 | $63 |
| Prednisone | 11 | $40 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $2,014 | $585,10436 claims |
| MerckKeytruda | $14 | $318,28830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Tampa
- Andrew KuykendallTampa$322K
- Jhanelle GrayTampa$229K
- Anitha ReddyTampa$224K
- Benjamin CreelanTampa$212K
- Anne HermannTampa$139K
- Mark LaflammeTampa$119K
- Shahla BariTampa$56K
- Haytham ElgammalMiami$2.2M
- Keith RubinFort Lauderdale$2M
- Michael SensionFort Lauderdale$1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.